Rivason

DVT & pulmonary embolism (PE) treatment & recurrence prevention in adults. Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation. VTE & prevention of VTE recurrence in childn & adolescents <18 yr & weighing 30-50 kg (15 mg tab) or >50 kg (20 mg tab) after at least 5 days of initial parenteral anticoagulation treatment.

Prevention of stroke & systemic embolism Adult 20 mg once daily. Patient w/ non-valvular atrial fibrillation w/ moderate (CrCl 30-49 mL/min) or severe (CrCl 15-29 mL/min) renal impairment 15 mg once daily. DVT & PE treatment & recurrence prevention Adult 15 mg bd (days 1-21); max daily dose: 30 mg. 20 mg once daily (day 22 onwards); max daily dose: 20 mg. Moderate (CrCl 30-49 mL/min) or severe (CrCl 15-29 mL/min) renal impairment 15 mg bd for the 1st 3 wk. 20 mg once daily thereafter. Consider dose reduction to 15 mg once daily if the patient's assessed risk for bleeding outweighs the risk for recurrent DVT & PE. Prevention of recurrent DVT & PE Adult 10 or 20 mg once daily following completion of at least 6 mth DVT or PE therapy; max daily dose: 10 or 20 mg. VTE & prevention of VTE recurrence Childn & adolescent <18 yr weighing ≥50 kg 20 mg once daily; max daily dose: 20 mg, 30-50 kg 15 mg once daily; max daily dose: 15 mg. Initiate treatment following at least 5 days of initial parenteral anticoagulation treatment.

Should be taken with food: May be crushed & mixed w/ water or apple puree immediately prior to use & administered orally for patients who are unable to swallow whole tab.

Hypersensitivity. Clinically significant active bleeding. Lesion or condition considered to be a significant risk for major bleeding (eg, current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophth surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities). Concomitant treatment w/ any other anticoagulants eg, unfractionated heparin (UFH), LWMH (eg, enoxaparin, dalteparin), heparin derivatives (eg, fondaparinux), oral anticoagulants (eg, warfarin, dabigatran etexilate, apixaban) except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic patients w/ Child-Pugh B & C. Pregnancy & lactation

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AF01 - rivaroxaban ; Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.

POM